Table 2.
Distribution and definition of bladder cancer pathologies
| Characteristics1 | N (%)2 | P-value3,4 | |
|---|---|---|---|
| Female | Male | ||
| Overall5 | |||
| UC | 2623 (91.8) | 9913 (96.0) | <0.001 |
| Non-UC | 234 (8.2) | 414 (4.0) | |
| SCC | 103 (3.6) | 146 (1.4) | |
| AC | 90 (3.2) | 205 (2.0) | |
| NET | 11 (0.4) | 18 (0.2) | |
| Undiff | 7 (0.2) | 25 (0.2) | |
| Sarcoma | 18 (0.6) | 14 (0.1) | |
| Others | 5 (0.2) | 6 (0.1) | |
| Period 05 | |||
| UC | 755 (88.9) | 2617 (95.1) | <0.001 |
| Non-UC | 94 (11.1) | 134 (4.9) | |
| SCC | 46 (5.4) | 51 (1.8) | |
| AC | 33 (3.9) | 59 (2.1) | |
| NET | 1 (0.1) | 1 (<0.1) | |
| Undiff | 4 (0.5) | 10 (0.4) | |
| Sarcoma | 9 (1.1) | 10 (0.4) | |
| Others | 1 (0.1) | 3 (0.1) | |
| Period 15 | |||
| UC | 968 (93.1) | 3666 (97.0) | <0.001 |
| Non-UC | 72 (6.9) | 114 (3.0) | |
| SCC | 27 (2.6) | 39 (1.0) | |
| AC | 31 (3.0) | 58 (1.5) | |
| NET | 5 (0.5) | 7 (0.2) | |
| Undiff | 2 (0.2) | 7 (0.2) | |
| Sarcoma | 4 (0.4) | 1 (<0.1) | |
| Others | 3 (0.3) | 2 (<0.1) | |
| Period 25 | |||
| UC | 900 (93.0) | 3630 (95.6) | <0.001 |
| Non-UC | 68 (7.0) | 166 (4.4) | |
| SCC | 30 (3.1) | 56 (1.5) | |
| AC | 26 (2.7) | 88 (2.3) | |
| NET | 5 (0.5) | 10 (0.3) | |
| Undiff | 1 (0.1) | 8 (0.2) | |
| Sarcoma | 5 (0.5) | 3 (<0.1) | |
| Others | 1 (0.1) | 1 (<0.1) | |
| Characteristics | Definition by ICD-O-36 |
|---|---|
| UC | 8120–8131 (including CIS, 8120/2), 8050 |
| Non-UC | |
| SCC | 8051–8078, 8083–8084 |
| AC | 8140–8231, 8250–8384, 8440–8490, 8550–8551, 8570–8576 |
| NET | 8013, 8240–8249, 8041–8045, 8680–8700 |
| Undiff | 8020–8021 |
| Sarcoma | 8801–8811, 8830, 8840–8921, 8930–8991, 9040–9044, 9120–9133, 9150, 9540–9581 |
| Others | The others |
UC, urothelial carcinoma; CIS, urothelial carcinoma in situ; SCC, squamous cell carcinoma; AC, adenocarcinoma; NET, neuroendocrine tumor; Undiff, undifferentiated carcinoma; non-UC, nonurothelial carcinoma; ICD-O-3, International Classification of Diseases for Oncology, Third Edition. Non-UC includes SCC, AC, NET, Undiff, Sarcoma, and Others.
Data for 13,184 patients with complete information on sex, pathology, age, and period.
Because of rounding, percentages may not total 100.
P-values for Fisher's exact tests comparing female and male patients.
All the P-values for χ2 tests comparing the proportions of non-UC female and male patients in Periods 0, 1, and 2 were <0.01.
Period: Total, 1954–2010; Period 0, 1954–1992; Period 1, 1993–2002; Period 2, 2003–2010.
Proportions of CIS in female and male patients: Period 0, 0.2% (2/849) and 0.2% (4/2751) (P = 0.63); Period 1, 0.5% (5/1040) and 0.5% (20/3780) (P > 0.99); Period 2, 11.2% (108/968) and 9.7% (369/3796) (P = 0.19).